English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

LAT1 (L-type amino acid transporter 1: SLC7A5) is an amino acid transporter. While normal cells intake amino acids by LAT2, tumor cells intake amino acids by LAT1. In pancreatic cancer, LAT1 is overexpressed in tumor cells, and high expression of LAT1 is a predictive factor of poor prognosis. To date, LAT1 competitive-inhibitors, such as BCH and JPH203, were developed, and they are reported to be effective against various cancer cells in vitro and xenograft model. However, LAT1 non-competitive-inhibitors have not been developed. Recently, we developed a LAT1 non-competitive-inhibitor and confirmed its anti-cancer effect against several cancer cells in vitro and xenograft model. Its oral administration also improved overall survival of genetically engineered mice with pancreatic ductal adenocarcinoma. After examining several nonclinical tests for the safety, we decided to move to the next step to acquire clinical proof of concept. To this end, we planned an investigator-initiated first in human clinical trial. After approved by institutional review board and clinical trial notification to PMDA, the trail has started and is ongoing. In the present session, we introduced our experienced process and various challenges to the investigator-initiated clinical trial. Company-Organized Symposium

Investigator-initiated clinical trial of an anti-cancer drug targeted on LAT1